TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8904617

Group type: COMPARATOR
Intervention: 60 mg LY293111 three times daily for 8 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: 120 mg LY293111 three times daily for 8 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: 200 mg LY293111 twice daily for 8 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1825970

Group type: EXPERIMENTAL
Intervention: TRI/LNG
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: GSD/30
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: DOG/20
Number of subjects: 89
Study: 6394044

Group type: EXPERIMENTAL
Intervention: Experiential treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Didactic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-conscious treatment
Number of subjects: 0
Study: 30844812

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 26802044

Group type: EXPERIMENTAL
Intervention: Intimate Partner Violence (IPV) victimization
Number of subjects: 1339

Group type: EXPERIMENTAL
Intervention: Intimate Partner Violence (IPV) perpetration
Number of subjects: 1339

Group type: EXPERIMENTAL
Intervention: Co-occurrence of IPV victimization and perpetration
Number of subjects: 1339

Group type: EXPERIMENTAL
Intervention: Factors associated with IPV
Number of subjects: 1339

Group type: EXPERIMENTAL
Intervention: Age-related IPV perpetration
Number of subjects: 1339

Group type: EXPERIMENTAL
Intervention: Gender symmetry in IPV victimization
Number of subjects: 1339
Study: 26887958

Group type: EXPERIMENTAL
Intervention: Antenatal depression-oriented acupuncture (weekly 1-hour treatments for 8 weeks from 24 to 31 weeks of gestation)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care (equivalent attention progressive muscle relaxation and routine antenatal depression hospital care)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Antenatal depression-oriented acupuncture
Number of subjects: 96
Study: 24804638

Group type: EXPERIMENTAL
Intervention: Embrace Advanced Scar Therapy device
Number of subjects: 65

Group type: COMPARATOR
Intervention: Surgeon's optimal care methods (control)
Number of subjects: 65
Study: 22335426

Group type: EXPERIMENTAL
Intervention: Timolol XE 0.5%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 50
Study: 20228401

Group type: EXPERIMENTAL
Intervention: Intensive therapy targeting systolic pressure <120 mm Hg
Number of subjects: 4733

Group type: COMPARATOR
Intervention: Standard therapy targeting systolic pressure <140 mm Hg
Number of subjects: 4733

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 4733

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 4733
Study: 17355281

Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg suppository
Number of subjects: 490

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 490
Study: 15836564

Group type: EXPERIMENTAL
Intervention: Aspirin (1000 mg)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study: 12188410

Group type: EXPERIMENTAL
Intervention: Chamomile extract spray (111 mg)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Normal saline spray (placebo)
Number of subjects: 161
Study: 10650360

Group type: EXPERIMENTAL
Intervention: Periostat (subantimicrobial dose of doxycycline) in conjunction with scaling and root planing (SRP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in conjunction with scaling and root planing (SRP)
Number of subjects: 0
Study: 7889583

Group type: EXPERIMENTAL
Intervention: PCA fentanyl
Number of subjects: 37

Group type: COMPARATOR
Intervention: PCA morphine
Number of subjects: 37
Study: 2240675

Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms.ml‐1 (group C‐5)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Clonidine 10 micrograms.ml‐1 (group C‐10)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Epinephrine 5 micrograms.ml‐1 (group E)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Plain lidocaine (group P)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Clonidine groups (C‐5 and C‐10)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (plain lidocaine and epinephrine)
Number of subjects: 92
Study: 30613

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clemastine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Disodium cromoglycate
Number of subjects: 0
Study: 30840026

Group type: EXPERIMENTAL
Intervention: Post-PCI FFR measurement
Number of subjects: 639
Study: 27235128

Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy (DC) and expansive duraplasty (ED) with hematoma evacuation (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hematoma evacuation only (Group B)
Number of subjects: 40
Study: 25514064

Group type: EXPERIMENTAL
Intervention: Dexmecamylamine (1 to 4 mg adjunct to SSRI/SNRI)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Placebo plus SSRI/SNRI
Number of subjects: 813
Study: 23435622

Group type: EXPERIMENTAL
Intervention: Enzastaurin (500 mg/day) with docetaxel (75 mg/m²) and prednisone (10 mg daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo with docetaxel (75 mg/m²) and prednisone (10 mg daily)
Number of subjects: 14
Study: 22231005

Group type: EXPERIMENTAL
Intervention: Effervescent tablets (Corega Tabs)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ultrasonic device (Ultrasonic Cleaner, model 2840 D)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Association of effervescent tablets and ultrasonic device
Number of subjects: 80

Group type: COMPARATOR
Intervention: Brushing with water (Control)
Number of subjects: 80
Study: 18801944

Group type: EXPERIMENTAL
Intervention: Knee immobilizer
Number of subjects: 88

Group type: COMPARATOR
Intervention: No knee immobilizer
Number of subjects: 88
Study: 17439507

Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched inulin (12 g/day, p.o.)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (12 g/day of maltodextrin, p.o.)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups (Oligofructose-enriched inulin and Placebo)
Number of subjects: 19
Study: 15075413

Group type: EXPERIMENTAL
Intervention: Adults with dementia
Number of subjects: 176

Group type: COMPARATOR
Intervention: Adults without dementia (controls)
Number of subjects: 176
Study: 16749287

Group type: EXPERIMENTAL
Intervention: Early mechanical revascularization with platelet glycoprotein IIb/IIIa inhibitors and drug-eluting stents, associated with strict glycemic control during hospital stay
Number of subjects: 0
Study: 10548198

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 20 ppm for 20 minutes
Number of subjects: 12
Study: 7485923

Group type: EXPERIMENTAL
Intervention: 200 U/kg rHuEPO
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 300 U/kg rHuEPO
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 400 U/kg rHuEPO
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 500 U/kg rHuEPO
Number of subjects: 49

Group type: COMPARATOR
Intervention: 0 U/kg rHuEPO (Control)
Number of subjects: 49
Study: 1959392

Group type: EXPERIMENTAL
Intervention: NCPAP treatment correcting apneas, sleep fragmentation, and hypoxemia
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: NCPAP treatment correcting apneas and sleep fragmentation while inducing intermittent hypoxemia
Number of subjects: 7

Group type: COMPARATOR
Intervention: NCPAP treatment under hypoxemic conditions
Number of subjects: 7
Study: 7265974

Group type: EXPERIMENTAL
Intervention: Subclavian route
Number of subjects: 100

Group type: COMPARATOR
Intervention: Internal jugular route
Number of subjects: 100
Study: 31483408

Group type: EXPERIMENTAL
Intervention: FluoroSim training (5 attempts each week for 2 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (1 attempt 1 week apart for 2 weeks)
Number of subjects: 45
Study: 28964563

Group type: EXPERIMENTAL
Intervention: Supportive parenting and consistent discipline
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Perceptions of positive parenting
Number of subjects: 503
Study: 27234988

Group type: EXPERIMENTAL
Intervention: Clinician training intervention on the 5As framework (Ask, Advise, Agree, Assist, Arrange), consisting of four 1-hour training sessions
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Clinician training intervention on the 5As framework
Number of subjects: 325
Study: 24239030

Group type: EXPERIMENTAL
Intervention: Interim methadone (IM; methadone without counseling) for the first 4 months of 12 months of methadone treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: 12 months of methadone with one of two counseling conditions
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Combined sample (both groups)
Number of subjects: 200
Study: 22857721

Group type: EXPERIMENTAL
Intervention: Heme arginate (1 mg/kg body weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 20056720

Group type: EXPERIMENTAL
Intervention: Mother and Baby (M&B) program (n=62)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Education only (EO) (n=73)
Number of subjects: 161
Study: 17003815

Group type: EXPERIMENTAL
Intervention: Vasopressin (non-pressor dose)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15895356

Group type: COMPARATOR
Intervention: PEG
Number of subjects: 193
Study: 11849459

Group type: EXPERIMENTAL
Intervention: Glycine betaine (GB) 4-g daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Folate and pyridoxine alone
Number of subjects: 36
Study: 11783251

Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SQFZI) combined with chemotherapy (Group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Chemotherapy (Group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SQFZI) (Group C)
Number of subjects: 120
Study: 7797977

Group type: COMPARATOR
Intervention: Splinting for 2 weeks following surgery
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Range-of-motion exercises starting on the first post-operative day
Number of subjects: 50
Study: 2194894

Group type: EXPERIMENTAL
Intervention: 500-mL gastric bubble (Ballobes) as an adjunct to diet, physical training, and behavioral modification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Very low-calorie diet and medical and dietary support
Number of subjects: 0
Study: 30548268

Group type: EXPERIMENTAL
Intervention: My Time intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 61
Study: 27377256

Group type: EXPERIMENTAL
Intervention: Higher intensity exercise
Number of subjects: 44

Group type: COMPARATOR
Intervention: Moderate intensity exercise
Number of subjects: 44

Group type: COMPARATOR
Intervention: Not meeting guidelines
Number of subjects: 44
Study: 26865517

Group type: EXPERIMENTAL
Intervention: teriflunomide 14 mg
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: teriflunomide 7 mg
Number of subjects: 742

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: teriflunomide (overall treatment)
Number of subjects: 742
Study: 25029806

Group type: EXPERIMENTAL
Intervention: Asphyxiated newborns
Number of subjects: 93

Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 93
Study: 22344189

Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ex‐PRESS implantation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 15
Study: 20679084

Group type: EXPERIMENTAL
Intervention: CsA 1% (group A)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: CsA 0.05% (group B)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Vehicle only (group C)
Number of subjects: 183
Study: 17721997

Group type: EXPERIMENTAL
Intervention: HPV16 L1E7 chimeric virus-like particles (CVLP) 75 mug
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: HPV16 L1E7 chimeric virus-like particles (CVLP) 250 mug
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: HPV16 L1E7 chimeric virus-like particles (CVLP)
Number of subjects: 39
Study: 15953223

Group type: EXPERIMENTAL
Intervention: Boussignac valve CPAP system
Number of subjects: 39

Group type: COMPARATOR
Intervention: Drager CF800 CPAP system
Number of subjects: 39
Study: 12468954

Group type: EXPERIMENTAL
Intervention: Otilonium bromide (40 mg, three times daily)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Otilonium bromide
Number of subjects: 378
Study: 9661596

Group type: EXPERIMENTAL
Intervention: 192/192 genotype in Caucasian men with IOM
Number of subjects: 171

Group type: COMPARATOR
Intervention: 192/192 genotype in healthy Caucasian men and women
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Subjects with one 194-bp allele
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: 192/192 genotype in men
Number of subjects: 171
Study: 7662399

Group type: EXPERIMENTAL
Intervention: Cholesterol education and intervention activities implemented by a state health department over three years.
Number of subjects: 11070

Group type: COMPARATOR
Intervention: Comparison community (no intervention).
Number of subjects: 11070
Study: 2583897

Group type: EXPERIMENTAL
Intervention: Oral L-Phe (100 mg/kg) + UVA exposure
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral L-Phe (100 mg/kg) + UVA exposure + topical 10% L-Phe cream
Number of subjects: 21
Study: 848701

Group type: EXPERIMENTAL
Intervention: Ventilation with oxygen and nitrogen
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ventilation with oxygen and nitrous oxide
Number of subjects: 48
Study: 30282100

Group type: EXPERIMENTAL
Intervention: Walking event (3.5 km walking course including tasks such as crossing at the crosswalk, walking up- and downstairs without a railing, walking along dirt roads, and walking up and down a slope)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (patients who could not participate in the walking event due to scheduling conflicts)
Number of subjects: 104
Study: 26868513

Group type: EXPERIMENTAL
Intervention: Health intervention package (classroom-based health education, hand-held health record, health check)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Health intervention package
Number of subjects: 388
Study: 25459096

Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen (NO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oxygen + oral analgesics
Number of subjects: 20
Study: 24101747

Group type: EXPERIMENTAL
Intervention: Mindfulness-based course (MBC) with eight weekly sessions of mindfulness education
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mindfulness-based course (MBC)
Number of subjects: 48
Study: 20813123

Group type: EXPERIMENTAL
Intervention: latanoprost 0.005%
Number of subjects: 68

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 68
Study: 17882008

Group type: EXPERIMENTAL
Intervention: Transdermal patch releasing 14 microg of E2 per day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vaginal ring releasing 7.5 microg of E2 per day
Number of subjects: 24
Study: 15756271

Group type: COMPARATOR
Intervention: 350 mg m(‐2) irinotecan (Group A)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: 250, 350 or 500 mg m(‐2) irinotecan based on individual patient tolerance (Group B)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Individual dose escalation based on risk factor optimisation (Group C)
Number of subjects: 164
Study: 12359676

Group type: EXPERIMENTAL
Intervention: Paroxetine (to 60 mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Desipramine (to 30 mg/day)
Number of subjects: 52
Study: 10367869

Group type: EXPERIMENTAL
Intervention: Cefotetan, 1g intravenously
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Cefazolin, 1g intravenously
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 7669541

Group type: EXPERIMENTAL
Intervention: Tailored preventive health program featuring health screening and smoking-cessation intervention
Number of subjects: 446
Study: 2158257

Group type: EXPERIMENTAL
Intervention: Rifabutin 150 mg
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Rifabutin 300 mg
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Rifabutin 450 mg
Number of subjects: 406

Group type: COMPARATOR
Intervention: Control (standard therapy)
Number of subjects: 406
Study: 6105515

Group type: EXPERIMENTAL
Intervention: Clofibrate
Number of subjects: 150000

Group type: COMPARATOR
Intervention: High serum cholesterol (control group)
Number of subjects: 150000

Group type: COMPARATOR
Intervention: Low cholesterol (control group)
Number of subjects: 150000
Study: 31462766

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 29786570

Group type: EXPERIMENTAL
Intervention: Metformin and pioglitazone
Number of subjects: 95

Group type: COMPARATOR
Intervention: Metformin and sulfonylureas
Number of subjects: 95
Study: 27457818

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 25085855

Group type: EXPERIMENTAL
Intervention: Sevoflurane-enriched blood cardioplegia
Number of subjects: 0
Study: 23408369

Group type: EXPERIMENTAL
Intervention: Working Memory (WM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Executive Control (EC)
Number of subjects: 60
Study: 20413040

Group type: COMPARATOR
Intervention: Atenolol-based regimen
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Amlodipine-based regimen
Number of subjects: 1006
Study: 18723286

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (0.1mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (0.025mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naloxone (after morphine administration)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Non-painful thermal sensations
Number of subjects: 12
Study: 16544087

Group type: EXPERIMENTAL
Intervention: 0.2-Hz electrical stimulation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study: 15494904

Group type: EXPERIMENTAL
Intervention: Fleroxacin-rifampicin
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standard therapy (flucloxacillin or vancomycin)
Number of subjects: 127
Study: 11046207

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.0-1.1% end tidal)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propofol (140 microg. kg‐1. min‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study: 9065360

Group type: EXPERIMENTAL
Intervention: Rivermead Motor Assessment (RMA)
Number of subjects: 3
Study: 8327367

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin administered 1 hr prior to the procedure
Number of subjects: 26

Group type: COMPARATOR
Intervention: Flavored syrup as placebo
Number of subjects: 26
Study: 2423813

Group type: EXPERIMENTAL
Intervention: Partially purified bean-derived amylase inhibitor with 50 g of starch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30357819

Group type: EXPERIMENTAL
Intervention: Revascularization together with Best Medical Therapy (BMT)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Best Medical Therapy (BMT) alone
Number of subjects: 158
Study: 29771014

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 115
Study: 25007225

Group type: EXPERIMENTAL
Intervention: Group stress management (GSM) (n = 77)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Individual stress management (ISM) (n = 78)
Number of subjects: 304
Study: 23156067

Group type: EXPERIMENTAL
Intervention: Continuing medical education/continuing professional development (five residential events + four short distance-learning refresher courses over one year)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuing medical education/continuing professional development
Number of subjects: 60
Study: 20234346

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg
Number of subjects: 425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study: 18329221

Group type: EXPERIMENTAL
Intervention: Modafinil (400 mg/day, n = 14)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Mirtazapine (60 mg/day, n = 13)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Treatment as usual (pericyazine, 2.5‐10 mg/day, n = 22)
Number of subjects: 49
Study: 15130899

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Intramuscular gold
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Pyramid
Number of subjects: 662
Study: 12909071

Group type: EXPERIMENTAL
Intervention: Oral amiodarone plus oral verapamil (group A+V)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Oral flecainide plus oral verapamil (group F+V)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Verapamil addition to group A and F patients
Number of subjects: 363

Group type: COMPARATOR
Intervention: Oral amiodarone (group A)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Oral flecainide (group F)
Number of subjects: 363
Study: 11286371

Group type: EXPERIMENTAL
Intervention: Medical Resonance Therapy Music (MRT-Music), 3 x 30 minutes per day for 14 days
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (relaxation during the same time period)
Number of subjects: 68
Study: 8803961

Group type: EXPERIMENTAL
Intervention: Lacidipine (2 mg b.i.d. for 8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined calcium and lacidipine administrations
Number of subjects: 0
Study: 1395455

Group type: EXPERIMENTAL
Intervention: OB + DZ (20 mg + 2 mg) T.I.D.
Number of subjects: 30

Group type: COMPARATOR
Intervention: OB alone (20 mg)
Number of subjects: 30
Study: 3892676

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Trimazosin
Number of subjects: 36